Drug Type Trispecific T-cell engager (TriTE) |
Synonyms VTS105 |
Target |
Action inhibitors, stimulants |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | China | 25 Apr 2025 | |
Hematologic Neoplasms | Preclinical | China | 25 Apr 2025 | |
Multiple Myeloma | Preclinical | China | 18 Apr 2025 |